Predictive Oncology ( (POAI) ) has issued an update.
Predictive Oncology Inc. announced that it has discontinued discussions with Renovaro Inc. regarding a proposed merger, clarifying that no binding agreement was ever reached despite contrary claims by Renovaro. The letter of intent for the merger, initially signed on January 1, 2025, and extended on February 28, 2025, expired on March 31, 2025, leaving Predictive Oncology with no further obligations to Renovaro. The company remains focused on advancing its core business in AI-driven drug discovery and development.
Spark’s Take on POAI Stock
According to Spark, TipRanks’ AI Analyst, POAI is a Neutral.
Predictive Oncology’s stock score is primarily driven by its challenging financial performance, characterized by declining revenues and negative profit margins. However, the technical analysis shows some positive momentum, which partially offsets the poor financial metrics. The valuation is unattractive due to negative earnings and lack of dividends.
To see Spark’s full report on POAI stock, click here.
More about Predictive Oncology
Predictive Oncology Inc. operates in the biotechnology industry, focusing on AI-driven drug discovery and drug development.
YTD Price Performance: 45.65%
Average Trading Volume: 3,810,523
Technical Sentiment Signal: Buy
Current Market Cap: $11.97M
For detailed information about POAI stock, go to TipRanks’ Stock Analysis page.